Dr Gaia Coppock comments on how collaborative care among nephrologists is transforming glomerular disease treatment.

FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...

In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...

Dr Gaia Coppock examines approaches to guide colleagues and patients through the quickly changing landscape of IgA ...

Vera Therapeutics received priority review from the FDA for its biologics license application for atacicept to treat adults ...

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete ...

Atacicept is a recombinant fusion protein that binds to and inhibits the activity of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand).

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

New kidney treatment techniques achieved impressive results in some studies, with one method showing 71% kidney recovery ...